Ned H. Kalin - Madison WI, US Patrick Henry Roseboom - Madison WI, US Steven Anil Nanda - Madison WI, US
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Various human urocortin II promoter sequences are disclosed. Nucleic acids and host cells that contain the promoter sequences are also disclosed. Further disclosed are various methods involving the use of these sequences. Also disclosed are methods of modulating the activity of a human urocortin II promoter sequence and methods of modulating urocortin II expression in a cell.
Promoter Sequences For Corticotropin Releasing-Factor Binding Protein And Use Thereof
Various human corticotropin-releasing factor binding protein promoter sequences are disclosed. Nucleic acids and host cells that contain the promoter sequences are also disclosed. Further disclosed are various methods involving the use of these sequences.
Promoter Sequences For Corticotropin Releasing-Factor Receptor Crf2Α And Method Of Identifying Agents That Alter The Activity Of The Promoter Sequences
Ned H. Kalin - Madison WI, US Patrick H. Roseboom - Madison WI, US Charles F. Landry - Madison WI, US Steven A. Nanda - Madison WI, US
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
C12N 15/85 C07H 21/04
US Classification:
435455, 536 241, 536 245
Abstract:
The DNA sequences of human and rat CRF receptor promoters are disclosed. Certain functional fragments of the human CRF receptor promoter are also disclosed. Further disclosed are a method of identifying functional fragments of human and rat CRF receptor promoters and a method of identifying agents that can alter the activity of the human or rat CRF receptor promoter.
Method Of Identifying Agents That Alter The Activity Of The Promoter Sequence For Corticotropin Releasing-Factor Receptor Crf2A
Ned Kalin - Madison WI, US Patrick Roseboom - Madison WI, US Charles Landry - Fitchburg WI, US Steven Nanda - Madison WI, US
International Classification:
A01K067/00 G01N033/567
US Classification:
800/003000, 435/007210
Abstract:
A method for identifying agents that alter the activity of the promoter region of CRF receptor is disclosed. In one embodiment, the method comprises the steps of (a) obtaining a cell line or organism, wherein the cell line or organism comprises a nucleic acid sequence encoding a promoter sequence of a heterologous CRF receptor operably attached to a reporter gene and (b) introducing a test agent into the cell or transgenic animal and evaluating the expression of the reporter gene product compared to a control cell line or transgenic animal wherein the agent has not been introduced into the cell line or transgenic animal.
Promoter Sequences For Corticotropin Releasing-Factor Receptor Crf2Alpha And Method Of Identifying Agents That Alter The Activity Of The Promoter Sequences
The DNA sequences of human and rat CRF receptor promoters are disclosed. Certain functional fragments of the human CRF receptor promoter are also disclosed. Further disclosed are a method of identifying functional fragments of human and rat CRF receptor promoters and a method of identifying agents that can alter the activity of the human or rat CRF receptor promoter.
Steven Nanda - Middleton WI, US Vaishali Bakshi - Madison WI, US Patrick Roseboom - Madison WI, US Ned Kalin - Madison WI, US
International Classification:
A61K038/47
US Classification:
424094610
Abstract:
A method of treating a patient is disclosed. In one embodiment, the method comprises the step of reducing the amount of mRNA encoding corticotropin-releasing factor receptor, wherein a portion of the mRNA encoding corticotropin-releasing factor receptor is destroyed and wherein the amount of corticotrophin releasing factor receptor is reduced.
Promoter Sequences For Urocortin Ii And The Use Thereof
Various human urocortin II promoter sequences are disclosed. Nucleic acids and host cells that contain the promoter sequences are also disclosed. Further disclosed are various methods involving the use of these sequences. Also disclosed are methods of modulating the activity of a human urocortin II promoter sequence and methods of modulating urocortin II expression in a cell.
A method of treating a patient is disclosed. In one embodiment, the method comprises the step of reducing the amount of mRNA encoding corticotropin-releasing factor receptor, wherein a portion of the mRNA encoding corticotropin-releasing factor receptor is destroyed and wherein the amount of corticotrophin releasing factor receptor is reduced.